> top > docs > PubMed:27866394 > annotations

PubMed:27866394 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-128 Sentence denotes Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress.
T2 129-244 Sentence denotes Otilonium bromide (OB) is a spasmolytic drug successfully used for the treatment of irritable bowel syndrome (IBS).
T3 245-385 Sentence denotes Its efficacy has been attributed to the block of L- and T-type Ca(2+) channels and muscarinic and tachykinin receptors in the smooth muscle.
T4 386-531 Sentence denotes Furthermore, in healthy rats, repeated OB administration modified neurotransmitter expression and function suggesting other mechanisms of action.
T5 532-803 Sentence denotes On this basis, we investigated whether repeated OB treatment prevented the functional and neurochemical changes observed in the colon of rats underwent to wrap restrain stress (WRS) a psychosocial stressor considered suitable to reproduce the main IBS signs and symptoms.
T6 804-944 Sentence denotes In control, WRS and OB/WRS rats functional parameters were measured in vivo and morphological investigations were done ex vivo in the colon.
T7 945-1036 Sentence denotes The results showed that OB counteracts most of the neurotransmitters changes caused by WRS.
T8 1037-1183 Sentence denotes In particular, the drug prevents the decrease in SP-, NK1r-, nNOS-, VIP-, and S100β-immunoreactivity (IR) and the increase in CGRP-, and CRF1r-IR.
T9 1184-1343 Sentence denotes On the contrary, OB does not affect the increase in CRF2r-IR neurons observed in WRS rats and does not interfere with the mild mucosal inflammation due to WRS.
T10 1344-1469 Sentence denotes Finally, OB per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.
T11 1470-1591 Sentence denotes Functional findings show a significantly reduction in the number of spontaneous abdominal contraction in OB treated rats.
T12 1592-1751 Sentence denotes The ability of OB to block L-type Ca(2+) channels, also expressed by enteric neurons, might represent a possible mechanism through which OB exerts its actions.
T1 0-128 Sentence denotes Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress.
T2 129-244 Sentence denotes Otilonium bromide (OB) is a spasmolytic drug successfully used for the treatment of irritable bowel syndrome (IBS).
T3 245-385 Sentence denotes Its efficacy has been attributed to the block of L- and T-type Ca(2+) channels and muscarinic and tachykinin receptors in the smooth muscle.
T4 386-531 Sentence denotes Furthermore, in healthy rats, repeated OB administration modified neurotransmitter expression and function suggesting other mechanisms of action.
T5 532-803 Sentence denotes On this basis, we investigated whether repeated OB treatment prevented the functional and neurochemical changes observed in the colon of rats underwent to wrap restrain stress (WRS) a psychosocial stressor considered suitable to reproduce the main IBS signs and symptoms.
T6 804-944 Sentence denotes In control, WRS and OB/WRS rats functional parameters were measured in vivo and morphological investigations were done ex vivo in the colon.
T7 945-1036 Sentence denotes The results showed that OB counteracts most of the neurotransmitters changes caused by WRS.
T8 1037-1183 Sentence denotes In particular, the drug prevents the decrease in SP-, NK1r-, nNOS-, VIP-, and S100β-immunoreactivity (IR) and the increase in CGRP-, and CRF1r-IR.
T9 1184-1343 Sentence denotes On the contrary, OB does not affect the increase in CRF2r-IR neurons observed in WRS rats and does not interfere with the mild mucosal inflammation due to WRS.
T10 1344-1469 Sentence denotes Finally, OB per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.
T11 1470-1591 Sentence denotes Functional findings show a significantly reduction in the number of spontaneous abdominal contraction in OB treated rats.
T12 1592-1751 Sentence denotes The ability of OB to block L-type Ca(2+) channels, also expressed by enteric neurons, might represent a possible mechanism through which OB exerts its actions.

LitCoin-entities

Id Subject Object Predicate Lexical cue db_id
11755 9-26 ChemicalEntity denotes otilonium bromide MESH:C013934
11756 51-67 ChemicalEntity denotes neurotransmitter MESH:D018377
11757 88-92 OrganismTaxon denotes rats NCBITaxon:10116
11758 129-146 ChemicalEntity denotes Otilonium bromide MESH:C013934
11759 148-150 ChemicalEntity denotes OB MESH:C013934
11760 213-237 DiseaseOrPhenotypicFeature denotes irritable bowel syndrome MESH:D043183
11761 239-242 DiseaseOrPhenotypicFeature denotes IBS MESH:D043183
11762 294-323 GeneOrGeneProduct denotes L- and T-type Ca(2+) channels NCBIGene:24239|NCBIGene:83810
11763 328-363 GeneOrGeneProduct denotes muscarinic and tachykinin receptors NCBIGene:1128|NCBIGene:6869
11764 410-414 OrganismTaxon denotes rats NCBITaxon:10116
11765 425-427 ChemicalEntity denotes OB MESH:C013934
11766 452-468 ChemicalEntity denotes neurotransmitter MESH:D018377
11767 580-582 ChemicalEntity denotes OB MESH:C013934
11768 669-673 OrganismTaxon denotes rats NCBITaxon:10116
11769 780-783 DiseaseOrPhenotypicFeature denotes IBS MESH:D043183
11770 824-826 ChemicalEntity denotes OB MESH:C013934
11771 831-835 OrganismTaxon denotes rats NCBITaxon:10116
11772 969-971 ChemicalEntity denotes OB MESH:C013934
11773 996-1013 ChemicalEntity denotes neurotransmitters MESH:D018377
11774 1086-1088 GeneOrGeneProduct denotes SP NCBIGene:24806
11775 1091-1095 GeneOrGeneProduct denotes NK1r NCBIGene:24807
11776 1098-1102 GeneOrGeneProduct denotes nNOS NCBIGene:24598
11777 1105-1108 GeneOrGeneProduct denotes VIP NCBIGene:117064
11778 1115-1120 GeneOrGeneProduct denotes S100β NCBIGene:25742
11779 1163-1167 GeneOrGeneProduct denotes CGRP NCBIGene:24241
11780 1174-1179 GeneOrGeneProduct denotes CRF1r NCBIGene:58959
11781 1201-1203 ChemicalEntity denotes OB MESH:C013934
11782 1236-1241 GeneOrGeneProduct denotes CRF2r NCBIGene:64680
11783 1269-1273 OrganismTaxon denotes rats NCBITaxon:10116
11784 1311-1331 DiseaseOrPhenotypicFeature denotes mucosal inflammation MESH:D052016
11785 1353-1355 ChemicalEntity denotes OB MESH:C013934
11786 1377-1380 GeneOrGeneProduct denotes Mr2 NCBIGene:81645
11787 1453-1457 GeneOrGeneProduct denotes ChAT NCBIGene:290567
11788 1575-1577 ChemicalEntity denotes OB MESH:C013934
11789 1586-1590 OrganismTaxon denotes rats NCBITaxon:10116
11790 1607-1609 ChemicalEntity denotes OB MESH:C013934
11791 1619-1641 GeneOrGeneProduct denotes L-type Ca(2+) channels NCBIGene:24239
11792 1729-1731 ChemicalEntity denotes OB MESH:C013934

LitCoin-sentences

Id Subject Object Predicate Lexical cue
T1 0-128 Sentence denotes Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress.
T2 129-244 Sentence denotes Otilonium bromide (OB) is a spasmolytic drug successfully used for the treatment of irritable bowel syndrome (IBS).
T3 245-385 Sentence denotes Its efficacy has been attributed to the block of L- and T-type Ca(2+) channels and muscarinic and tachykinin receptors in the smooth muscle.
T4 386-531 Sentence denotes Furthermore, in healthy rats, repeated OB administration modified neurotransmitter expression and function suggesting other mechanisms of action.
T5 532-803 Sentence denotes On this basis, we investigated whether repeated OB treatment prevented the functional and neurochemical changes observed in the colon of rats underwent to wrap restrain stress (WRS) a psychosocial stressor considered suitable to reproduce the main IBS signs and symptoms.
T6 804-944 Sentence denotes In control, WRS and OB/WRS rats functional parameters were measured in vivo and morphological investigations were done ex vivo in the colon.
T7 945-1036 Sentence denotes The results showed that OB counteracts most of the neurotransmitters changes caused by WRS.
T8 1037-1183 Sentence denotes In particular, the drug prevents the decrease in SP-, NK1r-, nNOS-, VIP-, and S100β-immunoreactivity (IR) and the increase in CGRP-, and CRF1r-IR.
T9 1184-1343 Sentence denotes On the contrary, OB does not affect the increase in CRF2r-IR neurons observed in WRS rats and does not interfere with the mild mucosal inflammation due to WRS.
T10 1344-1469 Sentence denotes Finally, OB per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.
T11 1470-1591 Sentence denotes Functional findings show a significantly reduction in the number of spontaneous abdominal contraction in OB treated rats.
T12 1592-1751 Sentence denotes The ability of OB to block L-type Ca(2+) channels, also expressed by enteric neurons, might represent a possible mechanism through which OB exerts its actions.

LitCoin-entities-OrganismTaxon-PD

Id Subject Object Predicate Lexical cue db_id
T1 88-92 OrganismTaxon denotes rats NCBItxid:10118|NCBItxid:10116|NCBItxid:10114
T4 410-414 OrganismTaxon denotes rats NCBItxid:10118|NCBItxid:10116|NCBItxid:10114
T7 669-673 OrganismTaxon denotes rats NCBItxid:10118|NCBItxid:10116|NCBItxid:10114
T10 831-835 OrganismTaxon denotes rats NCBItxid:10118|NCBItxid:10116|NCBItxid:10114
T13 1269-1273 OrganismTaxon denotes rats NCBItxid:10118|NCBItxid:10116|NCBItxid:10114
T16 1586-1590 OrganismTaxon denotes rats NCBItxid:10118|NCBItxid:10116|NCBItxid:10114

LitCoin_Mondo

Id Subject Object Predicate Lexical cue mondo_id
T1 213-237 DiseaseOrPhenotypicFeature denotes irritable bowel syndrome 0005052
T2 1245-1252 DiseaseOrPhenotypicFeature denotes neurons 0004466
T3 1311-1318 DiseaseOrPhenotypicFeature denotes mucosal 0020579
T4 1461-1468 DiseaseOrPhenotypicFeature denotes neurons 0004466
T5 1661-1668 DiseaseOrPhenotypicFeature denotes enteric 0043579
T6 1669-1676 DiseaseOrPhenotypicFeature denotes neurons 0004466

LitCoin-GeneOrGeneProduct-v0

Id Subject Object Predicate Lexical cue
T1 223-228 GeneOrGeneProduct denotes bowel
T2 229-237 GeneOrGeneProduct denotes syndrome
T3 285-290 GeneOrGeneProduct denotes block
T4 308-323 GeneOrGeneProduct denotes Ca(2+) channels
T5 343-353 GeneOrGeneProduct denotes tachykinin
T6 354-363 GeneOrGeneProduct denotes receptors
T7 371-384 GeneOrGeneProduct denotes smooth muscle
T8 504-509 GeneOrGeneProduct denotes other
T9 540-545 GeneOrGeneProduct denotes basis
T10 775-779 GeneOrGeneProduct denotes main
T11 1091-1095 GeneOrGeneProduct denotes NK1r
T12 1098-1102 GeneOrGeneProduct denotes nNOS
T13 1115-1119 GeneOrGeneProduct denotes S100
T14 1163-1167 GeneOrGeneProduct denotes CGRP
T15 1174-1179 GeneOrGeneProduct denotes CRF1r
T16 1236-1241 GeneOrGeneProduct denotes CRF2r
T17 1356-1359 GeneOrGeneProduct denotes per
T18 1399-1405 GeneOrGeneProduct denotes muscle
T19 1406-1410 GeneOrGeneProduct denotes wall
T20 1453-1457 GeneOrGeneProduct denotes ChAT
T21 1481-1489 GeneOrGeneProduct denotes findings
T22 1550-1559 GeneOrGeneProduct denotes abdominal
T23 1613-1618 GeneOrGeneProduct denotes block
T24 1626-1641 GeneOrGeneProduct denotes Ca(2+) channels

LitCoin-GeneOrGeneProduct-v2

Id Subject Object Predicate Lexical cue
T1 223-228 GeneOrGeneProduct denotes bowel
T2 229-237 GeneOrGeneProduct denotes syndrome
T3 343-353 GeneOrGeneProduct denotes tachykinin
T4 371-384 GeneOrGeneProduct denotes smooth muscle
T5 504-509 GeneOrGeneProduct denotes other
T6 1098-1102 GeneOrGeneProduct denotes nNOS
T7 1115-1119 GeneOrGeneProduct denotes S100
T8 1163-1167 GeneOrGeneProduct denotes CGRP
T9 1174-1179 GeneOrGeneProduct denotes CRF1r
T10 1399-1405 GeneOrGeneProduct denotes muscle
T11 1453-1457 GeneOrGeneProduct denotes ChAT
T12 1550-1559 GeneOrGeneProduct denotes abdominal

LitCoin-Disease-MeSH

Id Subject Object Predicate Lexical cue originalLabel
T1 213-237 DiseaseOrPhenotypicFeature denotes irritable bowel syndrome D043183
T2 239-242 DiseaseOrPhenotypicFeature denotes IBS D043183
T3 780-783 DiseaseOrPhenotypicFeature denotes IBS D043183
T4 1319-1331 DiseaseOrPhenotypicFeature denotes inflammation D007249

LitCoin-GeneOrGeneProduct-v3

Id Subject Object Predicate Lexical cue
T1 343-353 GeneOrGeneProduct denotes tachykinin
T2 371-384 GeneOrGeneProduct denotes smooth muscle
T3 1098-1102 GeneOrGeneProduct denotes nNOS
T4 1115-1119 GeneOrGeneProduct denotes S100
T5 1163-1167 GeneOrGeneProduct denotes CGRP
T6 1174-1179 GeneOrGeneProduct denotes CRF1r
T7 1453-1457 GeneOrGeneProduct denotes ChAT

LitCoin_Mondo_095

Id Subject Object Predicate Lexical cue mondo_id
T1 213-237 DiseaseOrPhenotypicFeature denotes irritable bowel syndrome 0005052
T2 239-242 DiseaseOrPhenotypicFeature denotes IBS 0007813|0005052
T4 709-712 DiseaseOrPhenotypicFeature denotes WRS 0009192
T5 780-783 DiseaseOrPhenotypicFeature denotes IBS 0007813|0005052
T7 816-819 DiseaseOrPhenotypicFeature denotes WRS 0009192
T8 827-830 DiseaseOrPhenotypicFeature denotes WRS 0009192
T9 1032-1035 DiseaseOrPhenotypicFeature denotes WRS 0009192
T10 1265-1268 DiseaseOrPhenotypicFeature denotes WRS 0009192
T11 1339-1342 DiseaseOrPhenotypicFeature denotes WRS 0009192

LitCoin-NCBITaxon-2

Id Subject Object Predicate Lexical cue
T1 88-92 OrganismTaxon denotes rats
T2 410-414 OrganismTaxon denotes rats
T3 669-673 OrganismTaxon denotes rats
T4 831-835 OrganismTaxon denotes rats
T5 1269-1273 OrganismTaxon denotes rats
T6 1453-1457 OrganismTaxon denotes ChAT
T7 1586-1590 OrganismTaxon denotes rats

LitCoin-MeSH-Disease-2

Id Subject Object Predicate Lexical cue ID:
T1 148-150 DiseaseOrPhenotypicFeature denotes OB DISEASE
T2 213-237 DiseaseOrPhenotypicFeature denotes irritable bowel syndrome D043183
T3 239-242 DiseaseOrPhenotypicFeature denotes IBS D043183
T4 425-427 DiseaseOrPhenotypicFeature denotes OB DISEASE
T5 580-582 DiseaseOrPhenotypicFeature denotes OB DISEASE
T6 780-783 DiseaseOrPhenotypicFeature denotes IBS D043183
T7 784-802 DiseaseOrPhenotypicFeature denotes signs and symptoms D012816
T8 824-826 DiseaseOrPhenotypicFeature denotes OB DISEASE
T9 969-971 DiseaseOrPhenotypicFeature denotes OB DISEASE
T10 1201-1203 DiseaseOrPhenotypicFeature denotes OB DISEASE
T11 1319-1331 DiseaseOrPhenotypicFeature denotes inflammation DISEASE|D007249
T13 1353-1355 DiseaseOrPhenotypicFeature denotes OB DISEASE
T14 1575-1577 DiseaseOrPhenotypicFeature denotes OB DISEASE
T15 1607-1609 DiseaseOrPhenotypicFeature denotes OB DISEASE
T16 1729-1731 DiseaseOrPhenotypicFeature denotes OB DISEASE

LitCoin-MONDO_bioort2019

Id Subject Object Predicate Lexical cue #label
T1 213-237 DiseaseOrPhenotypicFeature denotes irritable bowel syndrome D043183
T2 239-242 DiseaseOrPhenotypicFeature denotes IBS D043183
T3 780-783 DiseaseOrPhenotypicFeature denotes IBS D043183
T4 1319-1331 DiseaseOrPhenotypicFeature denotes inflammation D007249

LitCoin-Chemical-MeSH-CHEBI

Id Subject Object Predicate Lexical cue ID:
T1 9-26 ChemicalEntity denotes otilonium bromide C013934|http://purl.obolibrary.org/obo/CHEBI_135780
T3 51-67 ChemicalEntity denotes neurotransmitter ChemicalEntity
T4 129-146 ChemicalEntity denotes Otilonium bromide C013934|http://purl.obolibrary.org/obo/CHEBI_135780
T6 148-150 ChemicalEntity denotes OB C013934
T7 425-427 ChemicalEntity denotes OB C013934
T8 452-468 ChemicalEntity denotes neurotransmitter ChemicalEntity
T9 580-582 ChemicalEntity denotes OB C013934
T10 824-826 ChemicalEntity denotes OB C013934
T11 969-971 ChemicalEntity denotes OB C013934
T12 996-1013 ChemicalEntity denotes neurotransmitters ChemicalEntity
T13 1105-1108 ChemicalEntity denotes VIP http://purl.obolibrary.org/obo/CHEBI_80331
T14 1201-1203 ChemicalEntity denotes OB C013934
T15 1353-1355 ChemicalEntity denotes OB C013934
T16 1575-1577 ChemicalEntity denotes OB C013934
T17 1607-1609 ChemicalEntity denotes OB C013934
T18 1729-1731 ChemicalEntity denotes OB C013934

LitCoin-training-merged

Id Subject Object Predicate Lexical cue #label ID:
T18 1729-1731 ChemicalEntity denotes OB C013934
T17 1607-1609 ChemicalEntity denotes OB C013934
T16 1575-1577 ChemicalEntity denotes OB C013934
T15 1353-1355 ChemicalEntity denotes OB C013934
T14 1201-1203 ChemicalEntity denotes OB C013934
T13 1105-1108 ChemicalEntity denotes VIP http://purl.obolibrary.org/obo/CHEBI_80331
T12 996-1013 ChemicalEntity denotes neurotransmitters ChemicalEntity
T11 969-971 ChemicalEntity denotes OB C013934
T10 824-826 ChemicalEntity denotes OB C013934
T9 580-582 ChemicalEntity denotes OB C013934
T8 452-468 ChemicalEntity denotes neurotransmitter ChemicalEntity
T7 425-427 ChemicalEntity denotes OB C013934
T6 148-150 ChemicalEntity denotes OB C013934
T4 129-146 ChemicalEntity denotes Otilonium bromide http://purl.obolibrary.org/obo/CHEBI_135780|C013934
T3 51-67 ChemicalEntity denotes neurotransmitter ChemicalEntity
T1 9-26 ChemicalEntity denotes otilonium bromide http://purl.obolibrary.org/obo/CHEBI_135780|C013934
T30943 1453-1457 GeneOrGeneProduct denotes ChAT
T81166 1174-1179 GeneOrGeneProduct denotes CRF1r
T5 1163-1167 GeneOrGeneProduct denotes CGRP
T95090 1115-1119 GeneOrGeneProduct denotes S100
T57900 1098-1102 GeneOrGeneProduct denotes nNOS
T2 371-384 GeneOrGeneProduct denotes smooth muscle
T27732 343-353 GeneOrGeneProduct denotes tachykinin
T98576 1319-1331 DiseaseOrPhenotypicFeature denotes inflammation D007249
T25629 780-783 DiseaseOrPhenotypicFeature denotes IBS D043183
T49634 239-242 DiseaseOrPhenotypicFeature denotes IBS D043183
T90098 213-237 DiseaseOrPhenotypicFeature denotes irritable bowel syndrome D043183
T27386 1586-1590 OrganismTaxon denotes rats
T78129 1453-1457 OrganismTaxon denotes ChAT
T63440 1269-1273 OrganismTaxon denotes rats
T5399 831-835 OrganismTaxon denotes rats
T67639 669-673 OrganismTaxon denotes rats
T96389 410-414 OrganismTaxon denotes rats
T57992 88-92 OrganismTaxon denotes rats